Pomdoctor Limited (NASDAQ: POM) Long Term Investor Alert: Investigation of potential Wrongdoing

An investigation on behalf of current long-term investors in shares of Pomdoctor Limited (NASDAQ: POM) concerning potential breaches of fiduciary duties by certain directors and officers was announced.

Investors who are current long term investors in Pomdoctor Limited (NASDAQ: POM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: POM stocks follows a lawsuit filed against Pomdoctor Limited over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: POM stocks, concerns whether certain directors are liable in connection with the allegations made in that lawsuit.

China based Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. Pomdoctor Limited claims to be "a leading online medical services platform for chronic diseases in China." Specifically, Pomdoctor Limited states that Frost & Sullivan "ranked [them] sixth in China's internet hospital market" having achieved this by "develop[ing] a comprehensive platform that connects users with various healthcare providers, delivers cost-effective and customized healthcare solutions, and have cultivated a vibrant ecosystem around it."

Pomdoctor Limited (NASDAQ: POM) reported that its annual Total Revenue rose from 304.85 million CNY in 2023 to over 342.55 million CNY in 2024, and that its Net Loss declined from over 36.95 million CNY in 2023 to 37.39 million CNY in 2024.

On October 9, 2025, POMDOCTOR LIMITED announced the closing of its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS.

Since then shares of Pomdoctor Limited (NASDAQ: POM) declined to as low as $0.21 per share on February 18, 2026.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose that PomDoctor was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals, that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign, that PomDoctor's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price, and that as a result of the foregoing, defendants' positive statements about PomDoctor's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Pomdoctor Limited (NASDAQ: POM) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.